EFEnrico Farnetti

Enrico Farnetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Enrico Farnetti has a total of 235 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Concurrent heterozygous Von-Hippel–Lindau and transmembrane-protein-127 gene mutation causing an erythropoietin-secreting pheochromocytoma in a normotensive patient with severe erythrocytosis

    by Aurelio Negro, Gallia Graiani, Davide Nicoli, Enrico Farnetti, Bruno Casali, Ignazio Verzicco, Stefano Tedeschi, Angelo Ghirarduzzi, Valentina Cannone, Loredana D.E. Marco, et al.

    Background: Mutations of genes related to Krebs cycle enzymes, kinases or to pseudohypoxic signaling pathways, including Von-Hippel–Lindau (VHL) and transmembrane-protein-127 predispose to pheochromocytoma and paraganglioma development. Homozygous loss of function mutation of VHL (VHL 598C>T) gene can associate with polycythemia because of an altered hypoxia sensing. Patient: A 19-year-old normotensive man presented with headache, fatigue associated with severe erythrocytosis (hematocrit 76%), high hemoglobin (25.3 g/dl) in normoxic condition. Bone marrow biopsy showed marked hyperplasia of erythroid series. The Janus kinase 2 (V617F) mutation was absent. Abdominal computed tomography scan showed a 8-mm left adrenal pheochromocytoma with tracer uptake on 68GaDOTA-octreotate PET. Twenty-four-hour urinary metanephrine excretion was slightly increased, while normetanephrine, 3-methoxytyramine were normal. Adrenal veins sampling showed high left-side erythropoietin secretion. Results: Next-generation sequencing genetic analysis evidenced two concurrent heterozygous mutation of VHL598C>T and of transmembrane-protein-127 c.268G>A. Left side adrenalectomy improved symptoms, erythrocytosis, hemoglobin, and erythropoietin circulating levels. Adrenal histologic sections showed a pheochromocytoma with extensive immunostaining for erythropoietin, but also coexpression of chromogranin A, a marker of chromaffin tissue. Conclusion: Congenital polycythemia was clinically diagnosed, mimicking Chuvash polycythemia. Chuvash polycythemia is an autosomal recessive disorder that usually harbors a homozygous mutation of VHL598C>T but not predispose to pheochromocytoma development; in contrast our patient showed for the first time that the concurrent heterozygous VHL and TMEM mutations, resulted in a clinical phenotype of a normotensive patient with polycythemia due to erythropoietin-secreting pheochromocytoma that improved after adrenalectomy.


  • Open Access

    The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study

    by Francesco Iachetta, Candida Bonelli, Alessandra Romagnani, Raffaella Zamponi, Lorenzo Tofani, Enrico Farnetti, Davide Nicoli, Angela Damato, Maria Banzi, Bruno Casali, et al.

    Background Deleterious polymorphisms in the gene encoding DPD (DPYD) may result in severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the standard dose of fluorouracil is used. The best panel of single-nucleotide polymorphism (SNPs) of DPYD is not well defined. Methods In 2011, we began screening DPYD*2A in patients candidate for fluoropyrimidine-based chemotherapy. We planned a case-control study with all cases of DPYD*2A wild type who developed toxicity ≥G3 and with a cohort of patients who did not present severe toxicities. Then, we tested the additional SNPs: c.2846A>T, c.1679T>G, c.2194G>A. Results From 2011 to 2016, we screened 1827 patients for DPD deficiency; of those, 31 subjects (1.7%) showed DPYD*2A SNP. We selected 146 subjects who developed severe toxicities (Cases) and 220 patients who experienced no or mild toxicities (Controls); 53 patients carried one of the additional SNPs: 35 subjects (66%) fell into the Cases and 18 (34%) into the Controls (p < 0.0001). c.2194G>A was the most frequent SNP (12.5%) and showed a correlation with neutropenia. We confirmed that c.2846A>T and c.1679T>G were related to various toxicities. Conclusions The additional DPYD polymorphisms could enhance the prevention of fluoropyrimidine toxicity. c.2194G>A is the most frequent polymorphism and it was found to be associated with neutropenia.


  • Co-occurrence of an HSPG2 Missense Variant and Functional Polymorphisms in Atypical Schwartz–Jampel Syndrome Type 1 with Obesity: A Case Report

    by Ilenia Maini, Enrico Farnetti, Davide Nicoli, Elena Pavlidis, Carlotta Spagnoli, Grazia Gabriella Salerno, Daniele Frattini, Alessandro Iodice, Carlo Fusco

    Schwartz–Jampel syndrome type 1 (SJS1) is an autosomal recessive chondrodystrophic myotonia, linked to heparan sulfate proteoglycan 2 (HSPG2) variants. We describe a patient with typical features of SJS1, but not obesity. Clinical exome sequencing detected a rare missense variant in HSPG2, confirming our clinical diagnosis, but also two homozygous variants in SDC3 and ADRB3 genes, previously described to be associated with obesity. This additional genetic result could better explain our patient's phenotype. Despite the phenotypic variability associated to HSPG2 variants, it is advisable to carefully check other possible genetic causes underlying clinical signs not strictly related to the classical phenotype of SJS1. Informed consent was obtained from the patient's parents following a full explanation of the procedures undertaken. Written consent for publication of photographs and all other clinical details were obtained. * These authors equally contributed to this work.


  • Open Access

    Computational development of a molecular-based approach to improve risk stratification of endometrial cancer patients

    by Federica Torricelli, Davide Nicoli, Riccardo Bellazzi, Alessia Ciarrocchi, Enrico Farnetti, Valentina Mastrofilippo, Raffaella Zamponi, Giovanni Battista La Sala, Bruno Casali, Vincenzo Dario Mandato

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Federica Torricelli1, Davide Nicoli2, Riccardo Bellazzi3, Alessia Ciarrocchi1, Enrico Farnetti2, Valentina Mastrofilippo4, Raffaella Zamponi2, Giovanni Battista La Sala5, 6, Bruno Casali2 and Vincenzo Dario Mandato6 1Laboratory of Translational Research, Azienda USL Reggio Emilia-IRCCS, Reggio Emilia, Italy 2Laboratory of Molecular Biology, Azienda USL Reggio Emilia-IRCCS, Reggio Emilia, Italy 3Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy 4Unit of Surgical Gynecologic Oncology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy 5Unit of Obstetrics and Gynaecology, University of Modena and Reggio Emilia, Reggio Emilia, Italy 6Unit of Obstetrics and Gynaecology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy Correspondence to: Federica Torricelli, email: Federica.Torricelli@ausl.re.it Keywords: endometrial cancer; somatic mutations; prognosis; classification tree; next generation sequencing Received: March 27, 2018 Accepted: April 25, 2018 Published: May 22, 2018 ABSTRACT Histological classification and staging are the gold standard for the prognosis of endometrial cancer (EC). However, in morphologically intermediate and doubtful cases this approach results largely insufficient, defining the need for better classification criteria. In this work we developed an algorithm that based on EC genetic alterations and in combination with the current histological classification, improves EC patients prognostic stratification, in particular in doubtful cases. A panel of 26 cancer related genes was analyzed in 89 EC patients and somatic functional mutations were investigated in association with different histology and outcome. An unsupervised hierarchical clustering analysis revealed that two groups of patients with different tumor grade and different prognosis can be distinguished by mutational profile. In particular, the mutational status of APC, CTNNB1, PIK3CA, PTEN, SMAD4 and TP53 resulted to be principal drivers of prognostic clustering. Consistently, a decisional tree generated by a data mining approach summarizes the consequential molecular criteria for patients prognostic stratification. The model proposed by this work provides the clinician with a tool able to support the prognosis of EC patients and consequently drives the choice of the most appropriated therapeutic strategy and follow up.


  • A Novel CCND2 Mutation in a Previously Reported Case of Megalencephaly and Perisylvian Polymicrogyria with Postaxial Polydactyly and Hydrocephalus

    by I. Maini, E. Farnetti, S.G. Caraffi, I. Ivanovski, M.L. De Bernardi, C. Gelmini, M. Pollazzon, S. Rosato, S. Laurie, L. Matalonga, et al.

    In 2007, we reported a toddler girl with megalencephaly, perisylvian polymicrogyria, hydrocephalus, postaxial polydactyly, developmental delay, hypotonia, and minor dysmorphisms.[1] We identified her as being affected by megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and hydrocephalus syndrome (MPPH). MPPH had been described 3 years before by Mirzaa et al in five nonconsanguineous patients as a new disorder of brain overgrowth, partially overlapping with megalencephaly capillary malformation (MCAP).[2] Differences between these two conditions mainly involved somatic features: cutaneous vascular anomalies, syndactyly, and focal or segmental body overgrowth were more frequently linked to MCAP,[3] while polymicrogyria seemed more often associated with MPPH. In 2012, germline and postzygotic mutations in the PI3K–AKT pathway were identified in these two syndromes.[4] Mutations in genes PIK3R2 and AKT3 were more frequent in patients with MPPH, while mutations in the PIK3CA gene were recurrent in patients with MCAP.[3] Subsequently, mutations in CCND2, another gene of the same biochemical pathway, have been identified in 13 patients with MPPH.[5] [6] All reported CCND2 mutations prevent phosphorylation of residue p.Thr280, some by premature termination, but mostly by nonconservative variants at and around the phosphorylation site.[5] This results in the accumulation of unphosphorylated, ubiquitin-mediated degradation-resistant cyclin D2 in neural precursors, and is the same functional end point as observed for PI3K and AKT mutations.[5] In our patient, we initially investigated PIK3R2 and AKT3 by Sanger sequencing, and both resulted normal. Subsequently, we performed Whole Exome Sequencing and CCND2 sequence analysis and we identified a de novo missense mutation, NM_001759.3:c.839C > T (NP_001750.1:p.Thr280Ile). This specific variant has never been described before, but it affects the same critical residue mutated in five reported patients[5] ([Table 1]). Our patient is now 10 years old. She is affected by severe intellectual disability with absent speech and she is unable to walk unaided. From the age of 6 months, she has had structural focal epilepsy. Electroencephalogram showed diffuse abnormality of the background activity and multifocal interictal epileptiform discharges, from temporal and frontal regions. Recent observations reported drug-resistant epilepsy with seizures characterized by limbs hypertonia and upward rolling of the eyes. Seizures occurred several times a week and sometimes in clusters of two or three seizures per day with spontaneous recovery. It was suggested that MPPH patients carrying CCND2 mutations had polydactyly more frequently than those with PI3K–AKT pathway mutations.[5] Our patient also has this feature, but the mechanism underlying this phenotypic difference has yet to be explained.


  • Three Reportedly Unrelated Families With Liddle Syndrome Inherited From a Common Ancestor

    by Luca Pagani, Yoan Diekmann, Marco Sazzini, Sara De Fanti, Maurizio Rondinelli, Enrico Farnetti, Bruno Casali, Amelia Caretto, Francesca Novara, Orsetta Zuffardi, et al.

    Liddle syndrome is considered a rare Mendelian hypertension. We have previously described 3 reportedly unrelated families, native of an Italian area around the Strait of Messina, carrying the same mutation (βP617L) of the epithelial sodium channel. The aims of our study were (1) to evaluate whether a close genomic relationship exists between the 3 families through the analysis of mitochondrial DNA and Y chromosome; and (2) to quantify the genomic relatedness between the patients with Liddle syndrome belonging to the 3 families and assess the hypothesis of a mutation shared through identity by descent. HVRI (the hypervariable region I) of the mitochondrial DNA genome and the Y chromosome short tandem repeats profiles were analyzed in individuals of the 3 families. Genotyping 542 585 genome-wide single nucleotide polymorphisms was performed in all the patients with Liddle syndrome of the 3 families and some of their relatives. A panel of 780 healthy Italian adult samples typed for the same set of markers was used as controls. espite different lineages between the 3 families based on the analysis of mitochondrial DNA and Y chromosome, the 3 probands and their 6 affected relatives share the same ≈5 Mbp long haplotype which encompasses the mutant allele. Using an approach based on coalescent theory, we estimate that the 3 families inherited the mutant allele from a common ancestor ≈13 generations ago and that such an ancestor may have left ≈20 carriers alive today. The prevalence of Liddle syndrome in the region of origin of the 3 families may be much higher than that estimated worldwide.


  • Peptide Receptor Radionuclide Therapy–Induced Gitelman-like Syndrome

    by Aurelio Negro, Giovanni M. Rossi, Davide Nicoli, Annibale Versari, Enrico Farnetti, Rosaria Santi, Stefano De Pietri


  • Open Access

    EGFR status evaluation by liquid biopsy during first-line therapy in advanced NSCLC patients

    by M. Pagano, F. Zanelli, C. Bonelli, B. Casali, A. Cavazza, E. Farnetti, R. Gnoni, M. Larocca, D. Nicoli, C. Pinto

    Background: Over the past decade, personalized management based on the molecular features of tumours in patients with advanced non small-cell lung cancer (NSCLC) has entered routine clinical practice. The poor performance of many advanced NSCLC patients may limit invasive biopsies. The liquid biopsy is a diagnostic procedure performed on cancer-derived material obtained in blood samples. In this abstract, we will describe our experience with liquid biopsies.

  • The pre-emptive screening of multiple polymorphisms in gene-encoding dihydropyrimidine dehydrogenase (DPD) improve prevention of toxicity on patients candidate for fluoropyrimidine based-chemotherapy. An experience of the Reggio Emilia Cancer Center

    by F. Iachetta, A. Damato, C. Bonelli, A. Romagnani, M. Banzi, D. Nicoli, E. Farnetti, B. Casali, C. Pinto

    Background: Fluorouracil is one of the most used anti-tumor chemotherapeutic agents in oncology and dihydropyrimidine dehydrogenase (DPD) plays a key role in the metabolism of this drug . In patients with DPD deficiency the use of standard dose of fluorouracil can produce life-threatening toxicities. Deleterious polymorphisms in gene-encoding DPD (DPYD) may results in the severe reduction of DPD enzymatic activity. DPYD*2A (IVS14 + 1G > A) is the most common single-nucleotide polymorphism (SNP) associated with critical DPD deficiency. At present, most of the evidence supports screening for at least 3 SNPs (DPYD*2A, c.2846 A > T, c.1679T > G). The aim of this study is to confirm that the detection of additional polymorphisms of DPYD could enhance prevention of fluoropyrimidine toxicity.

  • The potential clinical impact of pre-emptive screening of multiple polymorphisms in gene-encoding DPD on patients candidate for fluoropyrimidine based-chemotherapy: An experience of the Northern Italy Cancer Centre.

    by Francesco Iachetta, Angela Damato, Candida Bonelli, Alessandra Romagnani, Maria Banzi, Davide Nicoli, Enrico Farnetti, Bruno Casali, Carmine Pinto

    2567 Background: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluorouracil. Deleterious polymorphisms in gene-encoding DPD ( DPYD) results in a DPD deficiency that causes life-threatening toxicities when the standard dose of fluorouracil is used. DPYD*2A (IVS14+1G > A) is the most common single-nucleotide polymorphism (SNP) associated with critical DPD deficiency. At present, most of the evidence supports screening for at least 3 SNPs (DPYD*2A, c.2846 A > T, c.1679T > G). The aim of this study is to confirm that the detection of additional polymorphisms of DPYD could enhance prevention of fluoropyrimidine toxicity. Methods: In 2011, we began to screen DPYD*2A in patients candidate for fluoropyrimidine based-chemotherapy. As the first step of the evaluation, we selected all cases of DPYD*2A wild type, from 2011 to 2012, who developed CTC-NCI-V.3 toxicity ≥ G3. In these patients, we researched the other 3 SNPs (c.2846 A > T, c.1679T > G, c.2194C > A). Mutational status was analyzed with real Time PCR. Results: From 2011 to 2016 we pre-emptively screened DPD deficiency in 1,863 patients and 32 subjects (1.6%), with results mutated for DPYD*2A. As the first step of the evaluation, 548 subjects were assessed from 2011 to 2012. We found 7 patients who were carriers of the DPYD*2A mutation (1.27%). Of the 541 wild type cases, 114 presented toxicities ≥ G3. In this subgroup, 22 patients (19%) proved to be mutated for the other SNPs of DPYP, as reported in the table below. Conclusions: Preliminary data show that in 22 (19%) of 114 patients who presented severe toxicity which was not correlated with DPYD*2A, we found other polymorphisms of gene encoding DPD. Out of the 3 SNPs evaluated, c.2194 C > A proved to be the most frequent, although it is the polymorphism that is least known and least studied. Such results suggest that the evaluation of additional polymorphisms could enhance the prevention of fluoropyrimidine toxicity. The results are expected to be clarified further in the second step, which is ongoing. [Table: see text]